Sunir J. Garg, MD, FACS, FASRS, discussed findings from a proof-of-concept clinical trial comparing OLN324, a bispecific antibody targeting VEGF and Ang-2, with faricimab in patients with diabetic macular edema in this video with Healio.
The results were presented at the American Society of Retina Specialists annual meeting.
OLN324 (Ollin Biosciences) demonstrated rapid drying of the macula that was “at least comparable, if not better,” than that seen with Vabysmo (faricimab, Genentech), according to Garg, chief of the retina service at Wills Eye Hospital and professor of ophthalmology at